How to read Use in Specific Populations on peptide labels (Section 8)

What this guide covers (and how it differs from sister pages)

How to read FDA peptide labeling already explains PLR Highlights vs Full PI, Drugs@FDA vs DailyMed, and why a trial paper is not an approved label. That hub briefly notes that safety and pharmacology sections answer different questions — but it does not walk through Use in Specific Populations (Section 8) or the Pregnancy and Lactation Labeling Rule (PLLR) in depth. This Day 37 guide is that deep companion.

It is also distinct from Clinical Pharmacology label literacy (Day 34 — Section 12 mechanism / PK, including how specific-population PK tables work), Warnings, Precautions, and Adverse Reactions literacy (Day 35 — Boxed Warning / 4 / 5 / 6), and Drug Interactions label literacy (Day 36 — Section 7). Today stays on specific-populations document literacy: PLLR subheads, removed letter categories, pediatric/geriatric/renal/hepatic CONCEPTS, GLP-1 washout language as a reason to open the current PI, and verification habits.

• Primary sources: 21 CFR 201.57(c)(9); FDA Pregnancy and Lactation Labeling Resources; FDA PLLR guidance / Small Entity Compliance Guide; FDA FAQs about labeling for prescription medicines; FDA Prescribing Information Resources; Drugs@FDA / DailyMed finished-product PIs for literacy examples.
• Two original GLPWiki diagrams: a Section 8.1–8.7 populations anatomy map, and a Section 8 / PLLR verification ladder.
• Out of scope: pregnancy advice, lactation advice, doses, titration schedules, compounding recipes, product or pharmacy recommendations, and medical advice.

What Section 8 Use in Specific Populations is for

Under 21 CFR 201.57(c)(9), the Use in Specific Populations section of Full Prescribing Information must contain required subsections for pregnancy, lactation, and — when applicable — females and males of reproductive potential, plus pediatric and geriatric use information, and other specific-population information when clinically significant differences exist (commonly renal and hepatic impairment as 8.6 / 8.7 when the label includes them).

The Pregnancy and Lactation Labeling Rule (PLLR), effective June 30, 2015 for new submissions with a phase-in for older applications, revised how 8.1–8.3 are written so healthcare professionals can assess benefit versus risk with structured narrative data rather than a single letter category. PLLR also requires labeling to be updated when information becomes outdated.

Highlights of Prescribing Information typically includes a concise Use in Specific Populations summary that points into Full PI Section 8. Treat Highlights as a gateway: orient there, then read the Full PI subsections for Risk Summary, Clinical Considerations, Data, and product-specific qualifications.

Section 8.1–8.7 map — which question each subsection answers

8.1 Pregnancy answers what is known about use during pregnancy for this finished product, including a pregnancy exposure registry statement when a registry exists, a Risk Summary drawn from human, animal, and/or pharmacologic sources (presented in that order when available), Clinical Considerations, and Data. Information formerly placed under a separate Labor and delivery heading is incorporated into Pregnancy under PLLR.

8.2 Lactation (formerly Nursing Mothers) addresses use while breastfeeding: Risk Summary, Clinical Considerations, and Data such as presence in milk and potential effects on the breastfed infant when information exists. 8.3 Females and Males of Reproductive Potential appears when necessary and may discuss pregnancy testing, contraception recommendations, and infertility information as they relate to the drug.

8.4 Pediatric Use and 8.5 Geriatric Use state what is known about use in those age groups for the labeled product. 8.6 Renal Impairment and 8.7 Hepatic Impairment appear when the label includes clinically significant differences or use CONCEPTS for those populations; dosage CONCEPT changes, when present, typically live in Dosage and Administration with cross-links — Section 8 describes the population finding, not a GLPWiki dosing table.

PLLR structure and why A/B/C/D/X letter categories are gone

FDA's Pregnancy and Lactation Labeling Resources explain that PLLR removes pregnancy letter categories A, B, C, D, and X. Those letters were widely misunderstood as a simple safety ranking. Modern labels replace them with narrative Risk Summary / Clinical Considerations / Data so readers can see the evidence type and its limits.

Literacy habit: if a social-media post says a peptide is "Category B" or "Category X," ask which finished product, which document date, and whether the claim is quoting a pre-PLLR label, a non-U.S. system, or an invented letter. Do not assign a letter category to a current PLLR-format U.S. PI.

When a pregnancy exposure registry is available, 8.1 includes information about it. Registries collect outcome data; a registry mention on a label is not personal counseling from this encyclopedia page.

Long washout / planned pregnancy language on some GLP-1 labels — CONCEPT literacy only

Some FDA-approved semaglutide finished-product labels discuss, in Section 8 (often 8.3 Females and Males of Reproductive Potential, with cross-links to 8.1), that the medicine should be discontinued at least 2 months before a planned pregnancy because of the long washout period / long half-life of semaglutide. Related 8.1 language may address what to do when pregnancy is recognized and may differ by labeled indication population.

Wording is product-specific and indication-context-specific. Injectable diabetes-labeled semaglutide, weight-management / CV-risk semaglutide, oral semaglutide, and dual-agonist finished products do not share identical Section 8 paragraphs. None of those sentences are pregnancy advice, lactation advice, or dosing advice from GLPWiki — they are reasons to open the current Agency-posted PI for the exact finished product and to involve a licensed clinician for personal decisions.

This encyclopedia page intentionally does not reproduce counseling algorithms, amounts, or schedules. For individual questions about pregnancy, lactation, or reproductive planning, contact a licensed clinician and use the Agency-posted label.

Pediatric, geriatric, renal, and hepatic — labeled CONCEPTS only

Pediatric Use (8.4) states whether safety and effectiveness have been established in pediatric patients, and for which age groups when applicable. Absence of a pediatric indication on one finished product is not evidence about another product that shares a molecule nickname, and it is not permission to invent a pediatric use from a trial paper.

Geriatric Use (8.5) describes what is known about older adults, including whether clinical studies included sufficient numbers of subjects aged 65 and over to determine differences, and any labeled response or safety differences.

Renal and hepatic impairment subsections (commonly 8.6 / 8.7 when present) describe clinically significant differences in response, safety, or use CONCEPTS. PK detail about organ impairment may also appear under Clinical Pharmacology; actionable dosage CONCEPTS, when labeled, usually sit in Dosage and Administration with cross-references. Literacy means following those cross-links rather than inventing a renal or hepatic rule from a half-life number on social media.

A practical Section 8 / PLLR verification path

Start with the claim: exact finished product name and dosage form, the population topic, and the document type being cited. Open Drugs@FDA for the Agency-posted PI PDF, then optionally DailyMed or FDALabel for structured SPL text. Read Full PI Section 8 in order — 8.1 PLLR subheads, 8.2, 8.3 when present, then 8.4–8.7 as labeled — and follow cross-links to Highlights, Contraindications, Warnings and Precautions, Dosage and Administration, and Clinical Pharmacology before quoting a single bullet.

Reject letter-category shortcuts and molecule-nickname paraphrases. Record product, subsection, subhead, revision date, and whether the claim is a Risk Summary statement, a Clinical Considerations point, a Data paragraph, or a Highlights gateway line.

For investigational compounds without an approved PI, use ClinicalTrials.gov and PubMed — and do not treat an NCT record or paper as substitute Section 8 labeling.

• Approved finished-product Section 8: Drugs@FDA label PDF.
• Structured SPL search: DailyMed / FDALabel — still verify against the Agency-posted PI when precision matters.
• PLLR outline and resources: FDA Pregnancy and Lactation Labeling Resources.
• Investigational only: ClinicalTrials.gov / PubMed — not approved labeling.

Product specificity: never invent from a molecule nickname

Prescribing Information is finished-product labeling. Two brands that share an active moiety can differ in formulation, route, approved indication populations, study programs, and therefore in how Section 8 is written. Copying Product A's pregnancy or pediatric paragraph into a claim about Product B is a document-type error.

The same rule applies when comparing an approved finished medicine with a compounded preparation or a research-use listing that happens to use a familiar molecule name. Those other items do not inherit Section 8 of an approved PI. For category boundaries, see approved versus investigational peptides and compounded versus FDA-approved GLP-1 medicines.

Where to go next on GLPWiki

Keep this page for Section 8 Use in Specific Populations / PLLR literacy. Use sister guides for adjacent document literacy without duplicating them.

• how-to-read-fda-peptide-labeling — whole-PI hub (Highlights, Indications, Drugs@FDA vs DailyMed).
• clinical-pharmacology-label-literacy — Section 12 ClinPharm / PK literacy, including specific-population PK tables.
• warnings-precautions-adverse-reactions-literacy — Boxed Warning / Sections 4–6 safety literacy.
• drug-interactions-label-literacy — Section 7 Drug Interactions literacy.
• titration-concepts-explained — how labels use escalation language without reproducing schedules.
• glp1-medications-by-indication — indication / finished-product distinctions.
• how-to-read-a-peptide-study — trial and evidence literacy.
• approved-vs-investigational-peptides — regulatory category boundaries.
• compounded-vs-fda-approved-glp1 — finished-product vs compounded distinctions.

Scope, disclaimer and review date

This guide is educational. It maps how to read Use in Specific Populations (Section 8) on FDA peptide and GLP-1 Prescribing Information under PLR and PLLR — including 8.1–8.3 structure, removal of pregnancy letter categories, 8.4–8.7 CONCEPTS, product-specific washout language as a reason to open the current PI, and a Drugs@FDA / DailyMed verify path. It does not provide pregnancy advice, lactation advice, reproductive-planning advice, doses, titration schedules, compounding recipes, administration tutorials, sourcing advice, or individual medical advice, and nothing here recommends starting, stopping, or continuing any medicine or research chemical. Decisions about health care belong with a licensed clinician and, for approved medicines, the official label.

Last reviewed: October 16, 2026. Labeling, approval status, and literature may have changed since; verify with Drugs@FDA, DailyMed, FDALabel, ClinicalTrials.gov, PubMed, and your clinician or pharmacist.